Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 8/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.45 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20832798 | 0.89 | CYP1A2 (0.49) | CYP1A2CYP3A4CLK4CYP2D6LMNA | |
| SCHEMBL18172283 | 0.87 | CYP1A2 (0.48) | CYP1A2CYP3A4CLK4CYP2D6LMNA | |
| SCHEMBL18181083 | 0.83 | CYP1A2 (0.58) | CYP1A2CYP3A4CLK4CYP2D6LMNA | |
| SCHEMBL21564083 | 0.82 | CYP1A2 (0.63) | CYP1A2CYP3A4CLK4CYP2D6LMNA | |
| SCHEMBL11235791 | 0.77 | CYP3A4 (0.48) | CYP1A2CYP3A4CLK4CYP2D6LMNA | |
| SCHEMBL18172288 | 0.76 | CYP1A2 (0.52) | CYP1A2CYP3A4CLK4CYP2D6LMNA | |
| SCHEMBL18172301 | 0.75 | PIM1 (0.44) | CYP1A2CYP3A4CLK4CYP2D6LMNA | |
| SCHEMBL19726803 | 0.74 | BRD4 (0.51) | CYP1A2CYP3A4CLK4LMNAHIF1A | |
| SCHEMBL20061676 | 0.73 | ATAD2 (0.44) | CYP1A2CYP3A4CLK4LMNAHIF1A | |
| SCHEMBL20832906 | 0.73 | CYP1A2 (0.46) | CYP1A2CYP3A4CLK4CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107750251-B | Isoxazolyl-substituted imidazopyridines | 塞尔森瑞科有限责任公司 | 2020-09-01 | — | — | CN | disclosed |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3286188-B1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3286188-B1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| EP-3286188-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | Cellcentric Ltd (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016170323-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016170323-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | EP300, HDAC3, HDAC1 | CYP1A2 2584/4885CYP3A4 1393/4885CLK4 3608/4885 |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | EP300, HDAC3, HDAC1 | CYP1A2 2584/4885CYP3A4 1393/4885CLK4 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.